|Bid||1.4500 x 1300|
|Ask||1.5000 x 1200|
|Day's Range||1.4500 - 1.4800|
|52 Week Range||0.9200 - 4.1700|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.40|
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937. Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.
Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2022.
If you want to know who really controls Leap Therapeutics, Inc. ( NASDAQ:LPTX ), then you'll have to look at the makeup...